Sanofi

YTD

ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories.

CEO

Olivier Antoine M. Charmeil

CEOOlivier Antoine M. Charmeil

Employees

76,493

Employees76,493

Headquarters

Paris, Ile-de-France

HeadquartersParis, Ile-de-France

Founded

1994

Founded1994

Employees

76,493

Employees76,493

SNY Key Statistics

Market cap

118.89B

Market cap118.89B

Price-Earnings ratio

20.23

Price-Earnings ratio20.23

Dividend yield

3.29%

Dividend yield3.29%

Average volume

5.05M

Average volume5.05M

High today

$48.75

High today$48.75

Low today

$47.92

Low today$47.92

Open price

$47.98

Open price$47.98

Volume

7.18M

Volume7.18M

52 Week high

$60.12

52 Week high$60.12

52 Week low

$44.62

52 Week low$44.62

SNY News

Simply Wall St 1d

Recursion’s First Clinical Signal And Sanofi Milestone Test AI Drug Thesis

Recursion Pharmaceuticals reported its first positive clinical proof-of-concept for REC-4881 in familial adenomatous polyposis. The company hit a fifth collabo...

TipRanks 2d

Regeneron, Sanofi announces EMA for CHMP adopted positive opinion for Dupixent

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, ado...

TipRanks 3d

Novavax sees FY26 adjusted total revenue $230M-$270M

Novavax (NVAX) transitioned lead commercial responsibility of Nuvaxovid beginning with the 2025-2026 COVID-19 vaccination season to Sanofi (SNY) for select mark...

Analyst ratings

67%

of 6 ratings

Buy

66.7%

Hold

33.3%

Sell

More SNY News

The Motley Fool 4d

Recursion Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. Wednesday, Feb. 25, 2026 at 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Najat Khan Chief Financial Officer — Ben Taylo...

Nasdaq 4d

FDA Approves Sanofi And Regeneron's Dupixent As First Medicine For Allergic Fungal Rhinosinusitis

(RTTNews) - Sanofi (SNY, SAN.PA) said FDA has approved Dupixent or dupilumab for the treatment of adult and pediatric patients aged 6 years and older with aller...

TipRanks 5d

Sanofi’s New Pediatric Fitusiran Trial Signals a Long-Term Hemophilia Push

Sanofi SA (SNY) announced an update on their ongoing clinical study. Sanofi Expands Pediatric Hemophilia Bet With New Fitusiran Phase 3 Study The study called...

TipRanks 6d

Sanofi Real-World Data Show Durable Two-Season Protection From Beyfortus in Infants

Sanofi ( (SNY) ) just unveiled an announcement. In February 2026, Sanofi highlighted new real-world data on its RSV antibody Beyfortus, showing strong performa...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.